Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somerset Emsam "approvable

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Somerset receives "approvable" letter Jan. 30 for its transdermal selegiline patch, Emsam. The Mylan/Watson joint venture indicated that FDA is requesting additional pharmacology/toxicology studies as well as postmarketing pharmacokinetic and safety studies. Tyramine dietary restrictions in labeling are also requested. The sponsors resubmitted the Emsam NDA Aug. 1, 2003 for treatment of depression following a March 2002 "not approvable" letter (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 14)...

You may also be interested in...



Somerset Emsam NDA Resubmission Adds Long-Term Indication, Higher Doses

Somerset’s resubmitted NDA for the selegiline patch Emsam seeks an indication for relapse prevention as well as treatment of depression.

Sandoz Looks To Biosimilars As It Reprioritizes In The US

Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.

Joint Tendering Creates ‘Attractive Nordic Market’

Joint tendering among Nordic countries can help reduce shortages of older, off-patent medicines. 

Topics

UsernamePublicRestriction

Register

PS002471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel